Palisade Bio is the latest to restructure, hunkering down on its lead program
Like so many other biotechs in the bear market, Palisade Bio is looking to play the reorg game and lay off parts of its staff.
The Carlsbad, CA-based biotech announced on Thursday that it will be putting a series of measures in place to “reduce operating expenses and preserve capital.” Palisade Bio CEO Tom Hallam said in a statement that due to current market conditions, and to ensure that it pushes forward in developing its lead candidate, 20% of the workforce will be let go.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.